The cardiovascular lab at UAM has expertise in human vascular tissue and blood, animal models and cell biology. Among standard techniques, molecular biology and immunohistochemistry are commonly used. In addition, we have employed different proteomic techniques (MALDI-TOF, IMAGING-MS, etc) in the search of novel biomarkers. We have also been involved in the validation of biomarkers in large patient cohorts.

Facilities description, including patient recruitment, human vascular blood/tissue, animal facilities and cell collections, proteomic technologies (including MALDI-TOF, protein arrays, metabolomics), different microscopic analytical tools, human cell culture laboratory are available in our institution.

Tasks in FAD:

TAA and AAA clinical and biological database Adventitial inflammation in AAA; Discovery of new biomarkers through proteomic and metabolomic approaches Diagnostic applications to biomarkers and functional imaging

Members of the FAD staff

Jesus Egido, MD, PhD, tissue & cell biology, pathology & animal models, WP1, 3, 4 Fernando Vivanco, PhD, proteomics WP3 Coral Barbas, PhD, metabolomics WP3 Mercedes de Frutos, PhD , metabolomics, WP3 Melina Vega, MD, vascular surgeon WP1 Cesar Aparicio, MD, vascular surgeon WP1 Luis Miguel Blanco-Colio, PhD, vascular biologist, proteomics & cell biology, WP3,4 Carmen Gomez-Guerrero, PhD, vascular biologist & cell biology, WP4 Jose Luis Martín-Ventura, PhD, vascular biologist, proteomics & cell biology, WP3,4 Sebastián Mas, PhD, vascular chemist, proteomics WP3,4

Main publication/patent linked to FAD tasks

 Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tunon J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110:2216-9.
 Blanco-Colio LM, Martin-Ventura JL, &, Martineau P, Hernandez G, Egido J. Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2007;27:168-74.
 Mas S, Touboul D, Brunelle A, Aragoncillo P, Egido J, Laprevote O, Vivanco F. Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst. 2007;132:24-6.
 Hernandez-Vargas P, & , Egido J, Gomez-Guerrero C. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res. 2006 ;99:1188-96.
 Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):916-22.